Aliases:This biomarker is also known as:
- regulator of G-protein signalling 5,
- regulator of G-protein signaling 5,
RGS5 is a member of the regulators of G protein signaling (RGS) family, which are signal transduction molecules that are involved in the regulation of heterotrimeric G proteins by acting as GTPase activators. RGS5 has been found to be involved in tumor angiogenesis and to antagonize the angiogenic effect of VEGF. Multiple alternatively spliced transcript variants have been found.
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
|QA State:||Under Review|
RGS5 has been found to be up-regulated in many types of malignant cells, including breast cancer.
RGS5 was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.
- Discovery and preliminary confirmation of novel early detection biomarkers for triple-negative breast cancer using preclinical plasma samples from the Women's Health Initiative observational study.
- Development and validation of sandwich ELISA microarrays with minimal assay interference.
- Plasma biomarker profiles differ depending on breast cancer subtype but RANTES is consistently increased.